Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Apixaban in Short Bowel Syndrome
NCT04344717Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2020
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban in short bowel syndrome (SBS) (5 arms), sponsored by UZ Leuven. Primary endpoint: Maximum Plasma Concentration. Started Dec 2020; status: completed.
02
Drugs
apixaban
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04344717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344717.